Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis (Q37904495)

25 August 2017

0 references

1 reference

title

Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis (English)

1 reference

25 August 2017

0 references

Efthimia Tasina

1

1 reference

25 August 2017

Anna-Bettina Haidich

series ordinal

2

1 reference

25 August 2017

Stamatia Kokkali

series ordinal

3

1 reference

25 August 2017

Malamatenia Arvanitidou

series ordinal

4

1 reference

25 August 2017

23 July 2011

1 reference

Lancet Infectious Diseases

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

834-844

1 reference

25 August 2017

11

1 reference

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: a glycylcycline antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: a new glycylcycline antimicrobial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: a new glycylcycline for treatment of serious infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

A review of tigecycline--the first glycylcycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

New antibiotic agents for bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

1 reference

7 January 2021

Establishing the role of tigecycline in an era of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: a critical update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline in critical care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline: first of a new class of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Statistical considerations in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

A note on graphical presentation of estimated odds ratios from several clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Arcsine test for publication bias in meta-analyses with binary outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Meta-analysis, Simpson's paradox, and the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Tigecycline-induced acute pancreatitis: case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Reporting bias in medical research - a narrative review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

The quality of safety reporting in trials is still suboptimal: survey of major general medical journals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Rapid development of Acinetobacter baumannii resistance to tigecycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Trial registration: a great idea switches from ignored to irresistible

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Clinical trial registration: looking back and moving ahead

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

Therapeutic options for infections due to vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970177-3

7 January 2021

10.1016/S1473-3099(11)70177-3

Identifiers

DOI

1 reference

25 August 2017

1 reference